2020 国际专家组共识:成人隐匿性自身免疫性糖尿病的管理

2020-08-26 国外内分泌相关专家小组(统称) Diabetes . 2020 Aug 26;

有相当大比例的成人糖尿病患者具有1型糖尿病(T1D)和2型糖尿病(T2D)的特征,这些患者在诊断是临床表现与T2D相似,但不需要胰岛素治疗且具有与T1D相关的免疫遗传性标志物。这种缓慢发展的自身免疫性

中文标题:

2020 国际专家组共识:成人隐匿性自身免疫性糖尿病的管理

英文标题:

Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel

发布日期:

2020-08-26

简要介绍:

有相当大比例的成人糖尿病患者具有1型糖尿病(T1D)和2型糖尿病(T2D)的特征,这些患者在诊断是临床表现与T2D相似,但不需要胰岛素治疗且具有与T1D相关的免疫遗传性标志物。这种缓慢发展的自身免疫性糖尿病称为隐匿性自身免疫性糖尿病。本文主要针对成人隐匿性自身免疫性糖尿病的管理提供共识指导。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2020 国际专家组共识:成人潜在自身免疫性糖尿病的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=b628a1c00196282a, title=2020 国际专家组共识:成人隐匿性自身免疫性糖尿病的管理, enTitle=Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel, guiderFrom=Diabetes . 2020 Aug 26;, authorId=0, author=, summary=有相当大比例的成人糖尿病患者具有1型糖尿病(T1D)和2型糖尿病(T2D)的特征,这些患者在诊断是临床表现与T2D相似,但不需要胰岛素治疗且具有与T1D相关的免疫遗传性标志物。这种缓慢发展的自身免疫性, cover=https://img.medsci.cn/2020831/1598887872399_2020535.jpg, journalId=0, articlesId=null, associationId=949, associationName=国外内分泌相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Wed Aug 26 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>有相当大比例的成人糖尿病患者具有1型糖尿病(T1D)和2型糖尿病(T2D)的特征,这些患者在诊断是临床表现与T2D相似,但不需要胰岛素治疗且具有与T1D相关的免疫遗传性标志物。这种缓慢发展的自身免疫性糖尿病称为隐匿性自身免疫性糖尿病。本文主要针对成人隐匿性自身免疫性糖尿病的管理提供共识指导。</p> </div> </div> </div>, tagList=[TagDto(tagId=216, tagName=糖尿病)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=216, guiderKeyword=糖尿病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=10992, appHits=260, showAppHits=0, pcHits=1091, showPcHits=10732, likes=2, shares=26, comments=26, approvalStatus=1, publishedTime=Mon Aug 31 23:31:25 CST 2020, publishedTimeString=2020-08-26, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Mon Aug 31 23:31:01 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 12:23:19 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 国际专家组共识:成人潜在自身免疫性糖尿病的管理.pdf)])
2020 国际专家组共识:成人潜在自身免疫性糖尿病的管理.pdf
下载请点击:
评论区 (18)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1191032, encodeId=21f91191032f6, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a075617739, createdName=云云玉玉, createdTime=Tue Feb 08 15:06:49 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975337, encodeId=93ed9e5337a1, content=好<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210621/e53513412eb64921b908e2e2c81a4da3/390f76ff363d4d6a8b5b239ae68cb77f.jpg, createdBy=d4d35529995, createdName=逍遥放荡不羁, createdTime=Mon Jun 21 09:45:34 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966691, encodeId=220f9666915e, content=好文章,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210503/c1899a05ca9c44b88c648bb52a2f82a9/b43f760eb0bc4f76adcf0d7d4714b5e7.jpg, createdBy=cc215461466, createdName=青峰弈谷, createdTime=Tue May 18 23:16:49 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944731, encodeId=54a5944e31fc, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b2b5459926, createdName=ms1000000702186414, createdTime=Tue Mar 02 12:21:42 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921287, encodeId=1c0792128e09, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333d5398737, createdName=ms7000000751082834, createdTime=Sat Jan 30 10:08:39 CST 2021, time=2021-01-30, status=1, ipAttribution=)]
    2022-02-08 云云玉玉

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1191032, encodeId=21f91191032f6, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a075617739, createdName=云云玉玉, createdTime=Tue Feb 08 15:06:49 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975337, encodeId=93ed9e5337a1, content=好<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210621/e53513412eb64921b908e2e2c81a4da3/390f76ff363d4d6a8b5b239ae68cb77f.jpg, createdBy=d4d35529995, createdName=逍遥放荡不羁, createdTime=Mon Jun 21 09:45:34 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966691, encodeId=220f9666915e, content=好文章,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210503/c1899a05ca9c44b88c648bb52a2f82a9/b43f760eb0bc4f76adcf0d7d4714b5e7.jpg, createdBy=cc215461466, createdName=青峰弈谷, createdTime=Tue May 18 23:16:49 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944731, encodeId=54a5944e31fc, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b2b5459926, createdName=ms1000000702186414, createdTime=Tue Mar 02 12:21:42 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921287, encodeId=1c0792128e09, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333d5398737, createdName=ms7000000751082834, createdTime=Sat Jan 30 10:08:39 CST 2021, time=2021-01-30, status=1, ipAttribution=)]
    2021-06-21 逍遥放荡不羁

    #学习#好文章

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1191032, encodeId=21f91191032f6, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a075617739, createdName=云云玉玉, createdTime=Tue Feb 08 15:06:49 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975337, encodeId=93ed9e5337a1, content=好<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210621/e53513412eb64921b908e2e2c81a4da3/390f76ff363d4d6a8b5b239ae68cb77f.jpg, createdBy=d4d35529995, createdName=逍遥放荡不羁, createdTime=Mon Jun 21 09:45:34 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966691, encodeId=220f9666915e, content=好文章,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210503/c1899a05ca9c44b88c648bb52a2f82a9/b43f760eb0bc4f76adcf0d7d4714b5e7.jpg, createdBy=cc215461466, createdName=青峰弈谷, createdTime=Tue May 18 23:16:49 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944731, encodeId=54a5944e31fc, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b2b5459926, createdName=ms1000000702186414, createdTime=Tue Mar 02 12:21:42 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921287, encodeId=1c0792128e09, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333d5398737, createdName=ms7000000751082834, createdTime=Sat Jan 30 10:08:39 CST 2021, time=2021-01-30, status=1, ipAttribution=)]
    2021-05-18 青峰弈谷

    好文章,谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1191032, encodeId=21f91191032f6, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a075617739, createdName=云云玉玉, createdTime=Tue Feb 08 15:06:49 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975337, encodeId=93ed9e5337a1, content=好<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210621/e53513412eb64921b908e2e2c81a4da3/390f76ff363d4d6a8b5b239ae68cb77f.jpg, createdBy=d4d35529995, createdName=逍遥放荡不羁, createdTime=Mon Jun 21 09:45:34 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966691, encodeId=220f9666915e, content=好文章,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210503/c1899a05ca9c44b88c648bb52a2f82a9/b43f760eb0bc4f76adcf0d7d4714b5e7.jpg, createdBy=cc215461466, createdName=青峰弈谷, createdTime=Tue May 18 23:16:49 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944731, encodeId=54a5944e31fc, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b2b5459926, createdName=ms1000000702186414, createdTime=Tue Mar 02 12:21:42 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921287, encodeId=1c0792128e09, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333d5398737, createdName=ms7000000751082834, createdTime=Sat Jan 30 10:08:39 CST 2021, time=2021-01-30, status=1, ipAttribution=)]
    2021-03-02 ms1000000702186414

    好文章

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1191032, encodeId=21f91191032f6, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a075617739, createdName=云云玉玉, createdTime=Tue Feb 08 15:06:49 CST 2022, time=2022-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975337, encodeId=93ed9e5337a1, content=好<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210621/e53513412eb64921b908e2e2c81a4da3/390f76ff363d4d6a8b5b239ae68cb77f.jpg, createdBy=d4d35529995, createdName=逍遥放荡不羁, createdTime=Mon Jun 21 09:45:34 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966691, encodeId=220f9666915e, content=好文章,谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210503/c1899a05ca9c44b88c648bb52a2f82a9/b43f760eb0bc4f76adcf0d7d4714b5e7.jpg, createdBy=cc215461466, createdName=青峰弈谷, createdTime=Tue May 18 23:16:49 CST 2021, time=2021-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=944731, encodeId=54a5944e31fc, content=好文章, beContent=null, objectType=guider, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b2b5459926, createdName=ms1000000702186414, createdTime=Tue Mar 02 12:21:42 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=921287, encodeId=1c0792128e09, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=333d5398737, createdName=ms7000000751082834, createdTime=Sat Jan 30 10:08:39 CST 2021, time=2021-01-30, status=1, ipAttribution=)]
    2021-01-30 ms7000000751082834

    0

拓展阅读

2009 中国糖尿病护理及教育指南

中华医学会糖尿病学分会(CDS,Chinese Diabetes Society) · 2009-10-30

2010CARI 2型糖尿病患者的肾功能评估

澳大利亚肾病指南委员会(CARI,Caring for Australasians with Renal Impairment) · 2010-01-01

2010CARI 2型糖尿病患者中慢性肾脏病的预防和管理

澳大利亚肾病指南委员会(CARI,Caring for Australasians with Renal Impairment) · 2010-01-01

2010 AOA(POA)糖尿病患者眼部健康

美国视觉协会(AOA,American Optometric Association) · 2010-01-01

中国糖尿病医学营养治疗指南 (2010年)

中华医学会糖尿病学分会(CDS,Chinese Diabetes Society) · 2010-01-01

运动与2型糖尿病联合声明

美国糖尿病学会(ADA,American Diabetes Association) · 2010-01-01